Ethnic Disparities in the Management of Inflammatory Bowel Disease in Israel and Impact on Outcomes.
作者信息
Boaz Elad, Ledder Oren, Bar-Gil Shitrit Ariella, Dagan Amir, Freund Michael R, Koslowsky Benjamin, Lujan Rona, Greenfeld Shira, Kariv Revital, Loewenberg Weisband Yiska, Lederman Natan, Matz Eran, Dotan Iris, Turner Dan, Yellinek Shlomo
机构信息
Department of General Surgery, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem, Israel.
Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
出版信息
Crohns Colitis 360. 2025 Mar 31;7(2):otaf025. doi: 10.1093/crocol/otaf025. eCollection 2025 Apr.
BACKGROUND
In this nationwide study, we aimed to explore healthcare services utilization, medical management, and disease outcomes of inflammatory bowel diseases (IBD) across the 2 major ethnic groups in Israel.
METHODS
We utilized a cohort including all patients diagnosed with IBD in Israel since 2005. The primary outcome was steroid dependency, with secondary outcomes including use of biologics, time to surgery, and hospitalizations. Outcomes were controlled for possible inherent differences in disease course and phenotype.
RESULTS
Of the 32 491 included patients, 18 252 (56%) had Crohn's disease (CD) and 14 239 (44%) had ulcerative colitis (UC); 10% were Arabs and 90% were Jews. Jewish ethnicity was associated with lower rates of steroid dependency compared to Arab ethnicity in both CD (HR = 0.7 [95% CI, 0.6-0.8]) and UC (HR = 0.7 [95% CI, 0.6-0.8]). The risk of IBD-related surgery in CD was higher in the Arab group at both 3 and 5 years (13% vs. 10%, 16% vs 14%, respectively, = .005). Arabs had more frequent IBD-related hospitalizations than Jews at 5 years (28% vs. 19% with at least 2 hospitalizations, < .001). In contrast, Jewish ethnicity was associated with more frequent use of biologics during the first year from diagnosis in patients with CD (HR = 1.3 [95% CI, 1.1-1.6]) but not with UC.
CONCLUSIONS
Arab ethnicity is associated with higher rates of hospitalizations, steroid dependency, and surgeries, and, on the other side, with lower utilization of biologics. Healthcare practitioners and policymakers should address potential cultural and systemic barriers in healthcare delivery in order to improve care across all populations.
相似文献
Crohns Colitis 360. 2025-3-31
J Can Assoc Gastroenterol. 2019-2
Isr Med Assoc J. 2019-10
World J Gastroenterol. 2019-10-14
本文引用的文献
Inflamm Bowel Dis. 2023-2-1
J Pediatr Gastroenterol Nutr. 2022-9-1
Clin Gastroenterol Hepatol. 2022-6
Inflamm Bowel Dis. 2021-10-20
Am J Gastroenterol. 2020-6
Pediatr Gastroenterol Hepatol Nutr. 2020-1